bds (bdx) new fda approval to improve vaginitis testing. becton dickinson and company bdx popularly known as bd recently received the fda&rsquo.s 510(k) clearance for the bd vaginal panel on the bd cor system. the panel is a comprehens

becton dickinson and company (bdx) presents at the 43rd annual cowen healthcare conference - slideshow.

(bdx) - analyzing becton dickinsons short interest. ) short percent of float has risen 36.49% since its last report. the company recently reported that it has

three reasons to add bd (bdx) stock to your portfolio now. becton dickinson and company bdx popularly known as bd is well-poised for growth in the coming quarters courtesy of a few product launches over the past few months. the optimis

ex-dividend reminder: becton dickinson perrigo and United States physical therapy. looking at the universe of stocks we cover at dividend channel on 3/9/23 becton dickinson &. co (symbol: bdx) perrigo company plc (symbol: prgo) and United

validea guru fundamental report for bdx - 3/3/2023. below is valideas guru fundamental report for becton dickinson and co (bdx). of the 22 guru strategies we follow bdx rates highest using our p/e/growth investor model based on the published st

relative strength alert for becton dickinson. the dividendrank formula at dividend channel ranks a coverage universe of thousands of dividend stocks according to a proprietary formula designed to identify those stocks that combine two import

bds (bdx) new fda approval to improve cervical cancer testing. becton dickinson and company bdx popularly known as bd recently received the fda&rsquo.s approval for the bd onclarity hpv (human papillomavirus) assay to be used with the

bds (bdx) latest combination test receives the fdas eua. becton dickinson and company bdx popularly known as bd recently received the fda&rsquo.s emergency use authorization (eua) for a new molecular diagnostic combination test for sar

becton dickinson and co. get eua for its covid-19 influenza a/b and rsv combination test. (rttnews) - becton dickinson and company (bdx) wednesday said it received emergency use authorization from the United States food and drug administration (

becton dickinson quarterly results guidance raises see street approval.

becton dickinson quarterly results guidance raises sees street approval.

becton dickinson (bdx) tops q1 earnings and revenue estimates. becton dickinson (bdx) came out with quarterly earnings of $2.98 per share beating the zacks consensus estimate of $2.67 per share. this compares to earnings of $3.64 per s

becton dickinson reports q1 earnings beat. raises fy23 guidance.

becton dickinson and company q1 profit decreases but beats estimates. (rttnews) - becton dickinson and company (bdx) revealed earnings for first quarter that decreased from last year but beat the street estimates.

becton dickinson boosts fy23 outlook - update. (rttnews) - while reporting financial results for the first quarter on thursday medical technology company becton dickinson and co. or bd (bdx) raised its adjusted earnings and revenue outlook for f

becton dickinson and co to present at the j.p. morgan healthcare conference. webcast at 12:45 pm et. (rttnews) - becton dickinson and company (bdx) will present at the 41st annual j.p. morgan healthcare conference.

bd certest biotec: mpox diagnostic test gets fdas eua. (rttnews) - medical technology company becton dickinson and co. or bd (bdx) and certest biotec announced monday emergency use authorization or eua from the United States food and drug admini